Foundayo leads to significant weight loss in menopausal women, including those with type 2 diabetes, in clinical trials.

Eli Lilly stock could grow 76% in 3 years driven by blockbuster drugs and new sales channels.

Eli Lilly's stock is projected to grow about 76% over the next three years, reaching around $2,091 per share. This growth is fueled by strong revenue increases from blockbuster drugs like Mounjaro and Zepbound, which contributed $6.7 billion in new r...